BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment
BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently engaged in equity compensation activities. He exercised 17,500 Restricted Stock Units (RSUs) on May 4, 2026, and subsequently sold 6,845 common shares on May 20, 2026, at a weighted average price of $1.085 per share to cover tax obligations from the RSU vesting. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, and after these transactions, Yocca retains a significant holding of common shares and RSUs.
MAY 23·Investing.com→
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock
BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently sold 6,845 shares of the company’s common stock for $7,426 to cover taxes related to vested restricted stock units. This transaction, executed under a Rule 10b5-1 trading plan, occurred after he acquired 17,500 shares through RSU vesting earlier in May. Following these events, Yocca directly holds 26,175 shares.
MAY 23·Stock Titan→
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations
BioXcel Therapeutics CEO Vimal Mehta reported exercising 49,758 Restricted Stock Units (RSUs) and subsequently selling 19,419 common shares at a weighted average price of $1.087 to cover tax obligations from the RSU vesting. This sale was conducted under a Rule 10b5-1 trading plan. After the transaction, Mehta directly holds 69,598 common shares, with additional indirect holdings through BioXcel LLC and his spouse.
